Observational studyBMC cardiovascular disorders2026
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction and asymptomatic hypotension: insights from a multicenter observational cohort study.
Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundRecent VICTOR study and the VICTORY pooled analysis demonstrate that vericiguat shows significant therapeutic value in a broader population of relatively stable heart failure with reduced ejection fraction (HFrEF) patients. However, the efficacy and safety of vericiguat in HFrEF patients receiving guideline-directed medical therapy (GDMT) who present with asymptomatic hypotension (systolic blood pressure (SBP) ≤ 100 mmHg) remain unclear and require further investigation.
methodsThis multicenter observational cohort study enrolled 164 patients with HFrEF and asymptomatic hypotension (SBP ≤ 100 mmHg), who voluntarily decide whether to receive vericiguat treatment. Propensity score matching (1:2) was employed to address non-random treatment allocation. The primary outcome was the first occurrence of a ≥ 30% reduction in N-terminal pro-B-type natriuretic peptide(NT-proBNP) from baseline at any assessment time point during follow-up. Kaplan-Meier (K-M) analysis and multivariable Cox regression models were applied to assess outcomes.
resultsA total of 61 vericiguat-treated patients and 36 controls completed the study. The incidence of significant NT-proBNP reduction in the vericiguat group was 68.8%, significantly higher than the 47.2% in the control group. Kaplan-Meier analysis demonstrated a significantly higher cumulative incidence of NT-proBNP reduction in the vericiguat group than in the control group (hazard ratio (HR) = 2.54, 95% confidence interval (CI): 1.42-4.55, P < 0.001). Multivariate Cox regression confirmed vericiguat as an independent predictor of significant NT-proBNP reduction (Model 3: HR = 2.34, 95% CI: 1.30-4.21, P = 0.004).
conclusionIn patients with HFrEF receiving GDMT with concomitant asymptomatic hypotension (SBP ≤ 100 mmHg), vericiguat treatment is significantly associated with a ≥ 30% reduction in NT-proBNP levels during follow-up. In terms of safety in this study, the small number of adverse events and the absence of major safety signals only suggest no statistically significant differences in safety between the two groups. Further large-scale studies with adequate statistical power are required to better evaluate the safety of vericiguat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.